Adcytherix

Adcytherix

Private
FranceHealthcare & Life Scienceswww.adcytherix.com

Last Round

Series A

Oct 16, 2025

Total Funding Raised

$154.2M

Momentum Score

50 /100

Company Overview

Adcytherix is a biopharmaceutical company focused on developing innovative antibody drug conjugates for cancer treatment, addressing high unmet medical needs to enhance patient care and outcomes.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCcancer therapyoncologyADC platformpreclinical biotechdrug discoverytargeted therapylinker technologycytotoxic payloadsdrug licensingbiologics R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adcytherix Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Adcytherix Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AOct 16, 2025
SeedJun 11, 2024

Key People

Founding team and executive leadership

Jaime Arango

Chief Financial Officer - CFO

Executive Team

Adcytherix Investors

Notable investors and investment history

InvestorRounds
Surveyor CapitalSeries A
RA Capital ManagementSeries A, Seed
Andera PartnersSeries A
Pontifax Venture CapitalSeries A, Seed
BpifranceSeries A
Dawn BiopharmaSeries A
aMoonSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Grew 50% QoQ, from 16 to 24 employees.

  • Mar 1, 2026

    Simon Sturge appointed to reinforce governance during clinical growth phase.

Adcytherix Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adcytherix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adcytherix's valuation, stock price, and market status.

Firmographic Details

HeadquartersFrance
Employee Range24
Year Founded2024
Last FundingOct 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.